**Name of Journal: *World Journal of Meta-Analysis***

**ESPS Manuscript NO: 26306**

**Manuscript Type: Systematic Reviews**

**Isolated hepatic perfusion for unresectable hepatic malignancies: A systematic review and meta-analysis**

Meng T *et al*. Isolated hepatic perfusion for hepatic malignancies

**Tian Meng, Guan-Qiao Li, Meng-Hua Dai**

**Tian Meng**, Department of General Surgery, Peking Union Medical College Hospital, Beijing 100730, China

**Guan-Qiao Li**, Peking Union Medical College, Beijing 100730, China

**Guan-Qiao Li**, Medical School, Tsinghua University, Beijing 100085, China

**Meng-Hua Dai**, Department of General Surgery, Peking Union Medical College Hospital, Beijing 100730, China

**Author contributions:** Meng T and Dai MH designed the research; Meng T and Li GQ performed the research; Meng T analyzed the data; Meng T and Li GQ wrote the paper; Dai MH reviewed the manuscript.

**Conflict-of-interest statement:** All the authors declare that they have no competing interests.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Correspondence to: Tian Meng, MD,** Department of General Surgery, Peking Union Medical College Hospital, No.1 Shuaifuyuan Wangfujing Dongcheng District, Beijing 100730, China. [42556973@qq.com](mailto:42556973@qq.com)

**Telephone:** +86-10-81568211

**Received:** April 3, 2016

**Peer-review started:** April 7, 2016

**First decision:** June 12, 2016

**Revised:** June 24, 2016

**Accepted:** August 15, 2016

**Article in press:**

**Published online:**

**Abstract**

**AIM:** To investigate the efficacy and safety of isolated hepatic perfusion (IHP) in the management of unresectable liver malignancies.

**METHODS:** Studies were identified manually and on-line by using PubMed and EMBASE database. We formulate the eligibility criteria according to the PICOS elements, and accessed the quality of studies using the MINORS instrument. Data from all included studies were carefully investigated. We calculated the pooled response rate and incidences of mortality reported from all eligible studies by using the Meta-Analyst software, And we computed a pooled relative risk (RR) and 95% confidence interval (CI) by using the Comprehensive Meta-Analysis software. Heterogeneity was quantified evaluated using *I2* statistic.

**RESULTS:** Eight studies, including 502 patients, were selected. Of these, six studies performed IHP, while the other two studies performed PIHP. The results showed that the pooled response rate was 60.8% (95%CI: 53.1%-68%), *I2* = 37.1%. The median overall survival was 20 mo (range: 12.1 to 25 mo) following IHP or PIHP. The pooled mortality rate was 5.4% (95%CI: 2.5%-11.2%), *I2* = 37.5%. Prognostic factors predict the response to IHP or survival, and were reported in six studies. Meta-analysis demonstrated that Gender was not associated with overall survival (RR = 0.877, 95%CI: 0.564-1.365); however, carcino-embryonic antigen ≤ 30 ng/mL was associated with a significant improvement in survival outcomes with CRC patients (RR = 2.082, 95%CI: 1.371-3.163), and there was no significant heterogeneity.

**CONCLUSION:** The present systemic review and meta-analysis suggest that IHP and PIHP are potentially efficient and safe techniques for unresectable liver primary and secondary malignancies.

**Key words:** Isolated hepatic perfusion; Unresectable; Hepatic malignancy; Systematic review; Meta-analysis

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The treatment of unresectable liver malignancies is an important and difficult clinical problem. Many studies suggested that isolated hepatic perfusion to be efficacious and safe in the management of unresectable liver malignancies. However, there has not yet been a systematic analysis to evaluate this method. Therefore we reviewed all the literature we could get and conducted a systemic review. In the present systemic review we demonstrated all details and results of this technique in every aspect and intensively investigated these data, so that it will help readers to understand this technique in a quick, comprehensive and objective way.

Meng T, Li GQ, Dai MH. Isolated hepatic perfusion for unresectable hepatic malignancies: A systematic review and meta-analysis. *World J Meta-Anal* 2016; In press

**INTRODUCTION**

Liver metastases are frequent manifestations of a variety of malignancies and are often the cause of mortality. The optimal curative treatment of primary or secondary liver tumors is surgical resection. However, less than one third of cases with malignant liver tumors are candidates for surgical intervention, whereas the rest exhibit unresectable feature due to the degree of liver involvement, insufficient liver remnant, or medical comorbidity[[1](#_ENREF_1),[2](#_ENREF_2)]. For these patients, conventional chemotherapy may be applied systemically but with little benefit and substantial toxicity.

Isolated hepatic perfusion (IHP) was developed over the past several decades as a complex open surgical technique to isolate the liver and perfuse the entire organ with high dosage chemotherapy. The complete vascular isolation and mobilization of liver allow maximal anti-tumor effect as well as minimal systemic toxicity[[3](#_ENREF_3),[4](#_ENREF_4)]. As an alternative approach of IHP, percutaneous Isolated hepatic perfusion (PIHP) obviate a large abdominal operation, and allows repeatable manipulation, which may enable the patients to get maximized therapeutic effects while having a faster recovery.

The management of patients with unresectable hepatic malignancies is a significant clinical problem. There are many uncertainties and controversies in treating these patients using either systemic or different regional therapies. Here we conduct this present study to systematically evaluate the existing literature of IHP and PIHP with specific focus on the profiles of efficacy, safety, and survival benefit.

**MATERIALS AND METHODS**

***Literature search strategy***

Studies were identified from the Pubmed and EMBASE electronic databases through January 2016 for relevant studies, using a combined MeSH terms and keywords search strategy. The following search terms were used: “isolated hepatic perfusion”, “tumor”, “cancer”, “neoplasm”, “carcinoma”, “metastases”, “nonresectable”. These themes were combined using the Boolean operator “AND”, “OR” in several combinations without restrictions. Articles were assessed based on the inclusion and exclusion criteria. We also reviewed the reference lists of retrieved papers and recent reviews.

***Selection criteria***

We attempted to formulate the eligibility criteria according to the PICOS elements. We performed an initial screening of titles or abstracts, and a second screening was based on full-text review. Studies were considered eligible if they met the following criteria: (1) Patients with unresectable primary or secondary liver malignancies; (2) Studies using IHP or percutaneous isolated hepatic perfusion (PIHP) will be included. Variations in drug, dosage, timing, frequency and duration will be tolerated; (3) Studies reporting one or more of these outcomes are eligible: the therapeutic response, toxicity, survival and prognostic factors; (4) Clinical trials and prospective cohort studies, with patients who underwent IHP or PIHP ≥ 25. If there were multiple articles based on the same sample, the one that reported the most detailed data will be included. If multiple publications from the same institution were identified, the most resent update with the largest number of patients will be included.

***Quality assessments***

We accessed the quality of studies using the MINORS instrument[[5](#_ENREF_5)]. Quality assessment was carried out independently by two reviewers. If both reviewers agreed, the study could be included to the systematic review. Discrepancies were in consultation with the senior author. The deviations between these included studies were taken into account during the quality assessment stage.

***Data extraction***

The data from all included studies were clearly tabulated. Information collected from these studies included study characteristics, patient and disease characteristics, parameters of IHP treatment, response rate, morbidity and mortality, survival information and prognostic factors.

***Data analysis***

We used a published analysis technique[[6](#_ENREF_6)] to calculate the pooled response rate and incidences of mortality reported from all eligible studies by using the Meta-Analyst software (version Beta 3.13, Tufts Medical Center). And we computed a pooled relative risk (RR) and 95%CI by using the Comprehensive Meta-Analysis software, version 2.2 (Biostat, Englewood, New Jersey). Heterogeneity was quantified evaluated using *I2* statistic. *I2* value of lower than 50% manifested with no or moderate heterogeneity, whereas *I2* value of greater than 50% was represented with large or extreme heterogeneity[[7](#_ENREF_7)]. The random effects model was used when heterogeneity existed.

**RESULTS**

***Identification of eligible studies***

The process of identifying eligible studies is summarized by the PRISMA chart[[8](#_ENREF_8)] in Figure 1. We initially retrieved 1002 articles from the PubMed and EMBASE database and two further articles were yielded through manual search of reference lists. After the removal of duplicates, 613 unique citations were identified. Of these, the majority was excluded after screening on titles or abstracts, mainly because they were animal experiments, reviews, case reports or not relevant to our analysis. Fifty four full-text articles were intensively reviewed. Twenty nine studies were considered to have low volume patients (< 25)[[9-37](#_ENREF_9)]. Seven articles did not assess for response, toxicity, survival or prognostic factors[[38-44](#_ENREF_38)]. Two studies employed biotherapy[[45](#_ENREF_45),[46](#_ENREF_46)], and eight articles were excluded due to more publication from the same center or based on the same cohort[[47-54](#_ENREF_47)]. The remaining eight articles were included[[55-62](#_ENREF_55)]. The characteristics of included studies are summarized in Table 1.

***Patient demographics and disease characteristics***

The patient and disease characteristics are summarized in Table 2. Eight studies including a total of 502 patients were reviewed. Except one article that did not report the sex ratio, the rate of male *vs* female reported by other studies was 1.23:1. The majority of patients had unresectable colorectal origin liver metastasis (56%) or melanoma (27%). Other pathology causing liver malignancies include hepatocellular carcinoma (14%), cholangiocarcinoma (0.6%), neuroendocrine neoplasms (0.8%), breast cancer (0.4%), renal cell carcinoma (0.4%), pancreatic adenocarcinoma (0.2%), appendiceal cancer (0.2%), adrenal adenocarcinoma (0.2%), retroperitoneal sarcoma (0.2%), *etc.* All the included studies had reported the eligibility criteria for patients, including patients who had unresectable, biopsy-proven hepatic malignancies, Eastern Cooperative Oncology Group performance status of 0-1, and other criteria to ensure that the patients would have good tolerance to the operation.

***Isolated hepatic perfusion details and response***

The isolated hepatic perfusion details and response rate are summarized in Table 3. Six of the eight studies performed IHP[[55](#_ENREF_55),[56](#_ENREF_56),[58-60](#_ENREF_58),[62](#_ENREF_62)], while the other two studies performed percutaneous isolated hepatic perfusion (PIHP)[[57](#_ENREF_57),[61](#_ENREF_61)]. Melphalan, TNF, or a combination of these two drugs was employed in most studies. The majority of studies reported to have a perfusion time of 60 min and the perfusate temperature was kept at 39.5-40 ℃. The pooled response rate was 60.8% (95%CI: 53.1%-68%), *I2*= 37.1% (Figure 2).

***Morbidity and mortality***

Toxicity, morbidity, and mortality are shown in Table 4. The pooled mortality rate was 5.4% (95%CI: 2.5%-11.2%), *I2* = 37.5% (Figure 3). The majority of studies reported a reversible hepatic toxicity, mainly manifested in transient elevations in transaminases and serum bilirubin, which return towards normal approximately by postoperative day 7. Besides hepatic toxicity, the most common hematologic toxicity was anemia, thrombocytopenia, and neutropenia. Significant nonhematologic complications were rare.

***Survival outcomes***

Seven studies had assessed the survival outcomes we listed in Table 5. Following IHP or PIHP, the median overall survival was reported in a range of 12.1 to 25 mo, with the median value to be 20 mo. There is one study using PIHP protocol that reported the median overall survival to be 25 mo, while that for patients who underwent IHP was 19 mo.

***Prognostic factors***

Prognostic factors predict the response to IHP or survival, and were reported in six studies (Table 6). Olofsson *et al*[55] found the volume of liver occupied with metastases (RR = 1.04, *P* = 0.02) and, the diameter of the largest metastasis (RR = 1.23, *P* = 0.01) to be significant for survival on univariate analysis. Magge *et al*[56] found that CRC patients who received FUDR within one year after IHP had better survival than those did not receive FUDR (RR = 0.3, *P* = 0.043). Fukumoto *et al*[57] reported that tumor response to PIHP (RR = 0.108, *P* < 0.001) and normalization of serum des-γ-carboxy prothrombin (DCP) after PIHP (RR = 0.28, *P* < 0.001) were both independent prognostic factors in HCC patients for survival. In Alexander’s study published in 2009, they carried out further research on prognostic factors. They found that patients who received IHP with postoperative hepatic arterial infusion chemotherapy with Floxuridine (FUDR) markedly prolonged the duration of response from 5.8 to 13 mo (*P* < 0.001). Patients who received higher doses of Melphalan tended to have higher response rates (*P* = 0.034). In survival analysis, it was found that the use of hepatic artery infusion (HAI) following IHP (for OS: RR = 1.78, *P* = 0.0039, for PFS: RR = 2.79, *P* < 0.0001) and preoperative carcino-embryonic antigen (CEA) ≤ 30 ng/mL (for OS: RR = 2.29, *P* = 0.0012, for PFS: RR = 2.35, *P* = 0.0006) were independently associated with hepatic PFS and OS. A study carried out by van Iersel *et al*[59] revealed that adjuvant chemotherapy was a positive prognostic factor for hepatic response to IHP (RR = 5.91, *P* = 0.009), while the female sex was borderline significant (RR = 2.65, *P* = 0.05). They confirmed adjuvant chemotherapy following IHP was a positive factor for PFS on multivariate analysis (RR = 0.05, *P* = 0.039), whereas on univariate analysis, no chemotherapy directed at liver metastases before IHP was a potential positive factor (*P* = 0.09). When assessed for OS, they found ≥10 liver metastases (RR = 1.95, *P* = 0.006), absence of hepatic artery perfusion (RR = 4.15, *P* = 0.003), presence of postoperative complications (RR = 1.54, *P* = 0.048) were all negative factors. Alexander *et al*[58] reported that patients with Ocular Melanoma who have a baseline lactate dehydrogenase (LDH) > 160 U/L were likely to have shorter survival courses (RR = 17.1, *P* = 0.0062).

According to the prognostic factors mentioned above, gender and preoperative CEA level predictive of survival were the only comparable factors with sufficient data for meta-analysis. Gender was not associated with overall survival (Figure 4); however, CEA ≤ 30 ng/mL was associated with a significant improvement in survival outcomes with CRC patients (RR = 2.082, 95%CI: 1.371-3.163) (Figure 5). There was no significant heterogeneity.

**DISCUSSION**

The ideal curative intervention of primary or secondary liver malignancies is surgical resection. Nonetheless, the diseases are unresectable in the majority of patients when diagnosed[[2](#_ENREF_2),[63](#_ENREF_63)]. Systemic chemotherapy remains the first-line of palliative therapy for metastatic disease and, little benefit is gained from long-term prospective, although it is associated with good initial response rates. Better tumor response has been shown to correlate with significant systemic toxicity in the setting of high dosage of chemotherapy, which limits the application of systemic chemotherapy[[64](#_ENREF_64)]. To circumvent such limitations, liver-directed regional therapies have emerged as novel therapeutic strategies. Regional therapies such as HAI, IHP, are based on the fact that higher doses of chemotherapy may improve the outcomes. HAI delivers chemotherapeutic regimens with a high rate of hepatic clearance directly to the hepatic artery, which provides the majority of blood supply to the tumor, thus avoiding systemic toxicity while achieving high concentrations of chemotherapeutic agents. The HAI method allows some regimens to achieve a 15-fold concentration in liver tumors compared to normal liver. IHP, which further blocks inferior vena cava (IVC), allows using more kinds of drugs and can reach up to 5 times higher tolerable drug doses than HAI without fear of systemic exposure[[65](#_ENREF_65)]. That is, IHP allows broader regimens and gets higher concentrations, which would be lethal if administered systemically.

IHP has been investigating and reporting worldwide since its first description five decades ago[[66](#_ENREF_66)]. Many studies evaluated the efficacy, safety, as well as the long-term survival of IHP, using generally accepted standards and yielded quantified results. Most studies acclaimed IHP to be efficacious and safe. Although promising, no current systemic evaluation of IHP is available yet. Therefore we reviewed all the literature we could get and conducted a systemic review. As an alternate of IHP, here we discussed PIHP and IHP together.

Our systemic meta-analysis demonstrated a pooled response rate following IHP/PIHP treatment to be 60.8% (95%Cl: 53.1%-68.0%), with each individual ranging from 29.6% to 71.6%. The median overall survival of IHP/PIHP was 20 mo (range: 12.1-25). This is particularly encouraging when considered with the low effects and high mortality with systemic chemotherapy. To our knowledge, there has been no randomized trial so far to compare the outcomes between IHP and systemic chemotherapy. A case-control study by van Iersal *et al*[[53](#_ENREF_53)] for the first time revealed no statistical significance of overall survival (OS) between IHP and systemic chemotherapy in unresectable colorectal cancer liver metastases (median overall survival: 25.0 mo for IHP group and 21.7 mo for chemotherapy, *P* = 0.29). However, selection bias has to be considered given the disagreement of age and, the duration of follow-up between the two groups. Further investigations including randomized controlled trials are of great necessity to evaluate the efficacy of IHP/PIHP in comparison to conventional systemic chemotherapy and other regional therapies.

Most studies found the procedure of IHP and PIHP to be safe. Among the selected studies, mortality was varied between 0% and 6%, and we drew the pooled mortality rate to be 5.4%. Most investigators observed a transient liver toxicity, which manifested by increases of bilirubin and transaminases, and would approximately decrease to normal level by postoperative day 7. Grade 3-4 post-operative toxicity and major complications were listed in our review (Table 4). Albeit the major systemic toxicity was avoided and the mortality was acceptable, we still should take notice of selecting ideal patients to undergo these procedures.

Due to limited number and the heterogeneity of outcomes reported by different studies, the only definite prognostic factors with sufficient data for meta-analysis were gender and preoperative CEA levels predictive of survival (Figures 4 and 5). The result indicated that CRC patients with low preoperative CEA (≤ 30 ng/mL) tended to have a better outcome compared to those whose preoperative CEA level > 30 ng/mL. Of note, IHP followed by HAI has been reported as a positive factor of survival by several investigations[[49](#_ENREF_49),[51](#_ENREF_51),[56](#_ENREF_56),[58](#_ENREF_58)]. However, due to the inconsistency or the absence of detailed parameters, we cannot get the results combined into an integrated one.

As a repeatable, less invasive method of hepatic perfusion *via* percutaneous administration, PIHP has been under clinical evaluation since the early 1990s[[37](#_ENREF_37),[67](#_ENREF_67)]. Among all the studies, the majority was small-scale observational studies and case reports[[21](#_ENREF_21),[24](#_ENREF_24),[36](#_ENREF_36),[68-70](#_ENREF_68)], and only two studies met our inclusion criteria. Fukumoto *et al*[57] performed 101 perfusions on 67 patients with hepatocellular carcinoma using Mitomycin C and/or Doxorubicin. They showed a hepatic response rate of 71.6% with overall survival of 25 mo, longer than the mean value of median OS of 19 mo reported by other six articles using IHP approach. Pingpank *et al*[[71](#_ENREF_71)] described a response rate of 29.6% in phase I study for patients with liver metastasis from various origins and of 34.1% in a phase III trial for patients with liver metastasis from melanoma. The phase III trial also reported the median hepatic PFS was longer in patients treated with PIHP than patients treated with standard of care (254 d *vs* 49 d). The distinction of response rates between these two sets of studies might be attributed to different cancer types and chemotherapy regimens. Additionally, in the phase I study, the response rate was not good perhaps due to the fact that the study was designed to evaluate toxicity and subsequently determine the MTD during dose escalation. In other words, the response rate was not their primary end point. Meanwhile, in the phase III study, the number of patients was relatively low, there were only a handful of patients who were refractory to systemic chemotherapy enrolled in the trial and associated with some withdrawers. All these factors might be selection bias for the study.

A number of limitations to this meta-analysis should not be ignored. All studies were non-randomized phase I/II clinical trials in design and may be liable to selection bias. Several aspects of heterogeneity may contribute to varied response and overall survival including pathological types of cancer, chemotherapy regimen, prior therapies *etc*. In addition, the inconsistency of prognostic factors described in individual studies made it difficult to compare and evaluate in meta-analysis.

In general, IHP and PIHP have unique and obvious advantages compared to systemic chemotherapy. For decades, investigations of IHP and PIHP were continually conducted, different regimens, the combination of chemotherapy, hyperthermia and hypoxemia, variations for the inflow and the venovenous bypass have been tested to improve the efficacy and safety. The present systemic review and meta-analysis suggest that IHP and PIHP are potentially efficient and safe techniques for unresectable liver primary and secondary malignancies, exhibiting a relatively high response rate, low mortality rate, and potentially prolonged overall survival. Though the role of hepatic perfusion is still not fully understood, there are vacant areas need to be explored. Can IHP make benefits to patients who were chemorefractory? Will IHP followed by HAI play a more effective role than IHP does? Will it improve the outcomes when IHP is a component to therapy and is combined with systemic chemotherapy or other regional therapies? How effective is it when applied to other types of tumor, e.g. pancreatic carcinoma? What kinds of patients would benefit most from this procedure? What is the appropriate timing of using IHP? And for percutaneous perfusion, which of the alternative techniques would be better, and how many times should they be repeated in different patients? These questions remain to be solved. Continued evaluation and great efforts are required to clarify its role and greater benefit each patient.

**COMMENTS**

***Background***

The optimal curative treatment of primary or secondary liver tumors is surgical resection. However, less than one third of cases with malignant liver tumors are candidates for surgical intervention. Conventional chemotherapy may be applied systemically but little benefit is gained from long-term prospective. Better tumor response has been shown to correlate with significant systemic toxicity in the setting of high dosage of chemotherapy, which limits the application of systemic chemotherapy. Isolated hepatic perfusion (IHP) as a liver-directed regional therapy, completely separating the liver's blood supply from the rest of the body through a surgical operation, and allows extremely high tolerable drug doses without fear of systemic exposure. As an alternative approach of IHP, percutaneous isolated hepatic perfusion (PIHP) is performed *via* a minimally invasive approach, using a double-balloon catheter to cut the liver's circulation. Here we conduct this study to investigate the efficacy, safety and survival benefit of these approaches.

***Research frontiers***

IHP has been investigating since its first description five decades ago. As a repeatable, less invasive method of hepatic perfusion, PIHP has been under clinical evaluation since the early 1990s. For decades, investigations of IHP and PIHP were continually conducted, different regimens, the combination of chemotherapy, hyperthermia and hypoxemia, variations for the inflow and the venovenous bypass have been tested to improve the efficacy and safety. Most studies acclaimed that IHP and PIHP have unique and obvious advantages compared to systemic chemotherapy. The role of hepatic perfusion in multidisciplinary treatment approaches for unresectable liver malignancies is still not fully understood. Continued evaluation and great efforts are required to clarify its role and greater benefit each patient.

***Innovations and breakthroughs***

IHP and PIHP have been successfully performed to treat primary or secondary unresectable liver cancers in various studies. In the present systemic review the authors reviewed the literature, carefully extracted and investigated the data, demonstrated all details and results of this technique in every aspect, so that it will help readers to understand this technique in a quick, comprehensive and objective way.

***Applications***

This review suggests that IHP and PIHP are potentially efficient and safe techniques for unresectable liver primary and secondary malignancies, exhibiting a relatively high response rate, low mortality rate, and potentially prolonged overall survival.

***Terminology***

IHP is a surgical technique that completely separating the liver's circulation from the rest of the body's circulatory system. The isolation of the liver's circulation allows an extremely high concentration of chemotherapy to the whole organ, while minimizing systemic toxicity. The procedure requires an open surgery which can be done only once. As an alternative approach of IHP, PIHP is performed *via* a minimally invasive approach, using a double-balloon catheter to cut the liver's circulation under fluoroscopic guidance. PIHP obviate a large abdominal operation, and allows repeatable manipulation, which may enable the patients to get maximized therapeutic effects while having a faster recovery.

***Peer-review***

This is an interesting review regarding the isolation hepatic perfusion for unresectable hepatic malignancies. The review of this topic may be useful for readers.

**REFERENCES**

1 **Tzeng CW**, Aloia TA. Colorectal liver metastases. *J Gastrointest Surg* 2013; **17**: 195-201; quiz p.201-2 [PMID: 23054896 DOI: 10.1007/s11605-012-2022-3]

2 **Leporrier J**, Maurel J, Chiche L, Bara S, Segol P, Launoy G. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. *Br J Surg* 2006; **93**: 465-474 [PMID: 16523446 DOI: 10.1002/bjs.5278]

3 **Reddy SK**, Kesmodel SB, Alexander HR. Isolated hepatic perfusion for patients with liver metastases. *Ther Adv Med Oncol* 2014; **6**: 180-194 [PMID: 25057304 DOI: 10.1177/1758834014529175]

4 **Facy O**, Doussot A, Zinzindohoué F, Holl S, Rat P, Ortega Deballon P. Isolated hepatic perfusion: principles and results. *J Visc Surg* 2014; **151 Suppl 1**: S25-S32 [PMID: 24582276 DOI: 10.1016/j.jviscsurg.2013.12.006]

5 **Slim K**, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. *ANZ J Surg* 2003; **73**: 712-716 [PMID: 12956787]

6 **Wallace BC**, Schmid CH, Lau J, Trikalinos TA. Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data. *BMC Med Res Methodol* 2009; **9**: 80 [PMID: 19961608 DOI: 10.1186/1471-2288-9-80]

7 **Higgins JP**, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003; **327**: 557-560 [PMID: 12958120 DOI: 10.1136/bmj.327.7414.557]

8 **Liberati A**, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009; **339**: b2700 [PMID: 19622552 DOI: 10.1136/bmj.b2700]

9 **van Iersel LB**, de Leede EM, Vahrmeijer AL, Tijl FG, den Hartigh J, Kuppen PJ, Hartgrink HH, Gelderblom H, Nortier JW, Tollenaar RA, van de Velde CJ. Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: A phase I study. *Eur J Surg Oncol* 2014; **40**: 1557-1563 [PMID: 25125340 DOI: 10.1016/j.ejso.2014.06.010]

10 **Tanaka M**, Fukumoto T, Kido M, Takebe A, Kuramitsu K, Kinoshita H, Komatsu S, Fukushima K, Urade T, So S, Shinzeki M, Matsumoto I, Ajiki T, Terashima K, Fujii O, Demizu Y, Fuwa N, Ku Y. [Analysis of the safety and efficacy of percutaneous isolated hepatic perfusion after particle therapy for advanced hepatocellular carcinoma]. *Gan To Kagaku Ryoho* 2013; **40**: 1681-1683 [PMID: 24393887]

11 **Magge D**, Zureikat AH, Bartlett DL, Holtzman MP, Choudry HA, Beumer JH, Pingpank JF, Holleran JL, Strychor S, Cunningham DE, Jones HL, Zeh HJ. A phase I trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases from colorectal cancer. *Ann Surg Oncol* 2013; **20**: 2180-2187 [PMID: 23575907 DOI: 10.1245/s10434-013-2960-3]

12 **Varghese S**, Xu H, Bartlett D, Hughes M, Pingpank JF, Beresnev T, Alexander HR. Isolated hepatic perfusion with high-dose melphalan results in immediate alterations in tumor gene expression in patients with metastatic ocular melanoma. *Ann Surg Oncol* 2010; **17**: 1870-1877 [PMID: 20221901 DOI: 10.1245/s10434-010-0998-z]

13 **Zeh HJ**, Brown CK, Holtzman MP, Egorin MJ, Holleran JL, Potter DM, Bartlett DL. A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer. *Ann Surg Oncol* 2009; **16**: 385-394 [PMID: 19034580 DOI: 10.1245/s10434-008-0179-5]

14 **van Etten B**, de Wilt JH, Brunstein F, Eggermont AM, Verhoef C. Isolated hypoxic hepatic perfusion with melphalan in patients with irresectable ocular melanoma metastases. *Eur J Surg Oncol* 2009; **35**: 539-545 [PMID: 18760560 DOI: 10.1016/j.ejso.2008.07.004]

15 **Verzaro R**, Zeh H, Bartlett D. A safe and fast technique for isolated hepatic perfusion. *J Surg Oncol* 2008; **98**: 393-396 [PMID: 18646044 DOI: 10.1002/jso.21113]

16 **Verhoef C**, de Wilt JH, Brunstein F, Marinelli AW, van Etten B, Vermaas M, Guetens G, de Boeck G, de Bruijn EA, Eggermont AM. Isolated hypoxic hepatic perfusion with retrograde outflow in patients with irresectable liver metastases; a new simplified technique in isolated hepatic perfusion. *Ann Surg Oncol* 2008; **15**: 1367-1374 [PMID: 18239976 DOI: 10.1245/s10434-007-9714-z]

17 **Mocellin S**, Pilati P, Da Pian P, Forlin M, Corazzina S, Rossi CR, Innocente F, Ori C, Casara D, Ujka F, Nitti D, Lise M. Correlation between melphalan pharmacokinetics and hepatic toxicity following hyperthermic isolated liver perfusion for unresectable metastatic disease. *Ann Surg Oncol* 2007; **14**: 802-809 [PMID: 17103263 DOI: 10.1245/s10434-006-9108-7]

18 **van Etten B**, Brunstein F, van IJken MG, Marinelli AW, Verhoef C, van der Sijp JR, Guetens G, de Boeck G, de Bruijn EA, de Wilt JH, Eggermont AM. Isolated hypoxic hepatic perfusion with orthograde or retrograde flow in patients with irresectable liver metastases using percutaneous balloon catheter techniques: a phase I and II study. *Ann Surg Oncol* 2004; **11**: 598-605 [PMID: 15172933 DOI: 10.1245/ASO.2004.09.021]

19 **Noter SL**, Rothbarth J, Pijl ME, Keunen JE, Hartgrink HH, Tijl FG, Kuppen PJ, van de Velde CJ, Tollenaar RA. Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver. *Melanoma Res* 2004; **14**: 67-72 [PMID: 15091197 DOI: 10.1097/00008390-200402000-00011]

20 **Lise M**, Pilati P, Da Pian P, Mocellin S, Ori C, Casara D, Rossi CR, Darisi T, Corazzina S, Nitti D. Hyperthermic isolated liver perfusion for unresectable liver cancers: pilot study. *J Chemother* 2004; **16** Suppl 5: 37-39 [PMID: 15675475]

21 **Ku Y**, Iwasaki T, Tominaga M, Fukumoto T, Takahashi T, Kido M, Ogata S, Takahashi M, Kuroda Y, Matsumoto S, Obara H. Reductive surgery plus percutaneous isolated hepatic perfusion for multiple advanced hepatocellular carcinoma. *Ann Surg* 2004; **239**: 53-60 [PMID: 14685100 DOI: 10.1097/01.sla.0000103133.03688.3d]

22 **Grover AC**, Libutti SK, Pingpank JF, Helsabeck C, Beresnev T, Alexander HR. Isolated hepatic perfusion for the treatment of patients with advanced liver metastases from pancreatic and gastrointestinal neuroendocrine neoplasms. *Surgery* 2004; **136**: 1176-1182 [PMID: 15657573 DOI: 10.1016/j.surg.2004.06.044]

23 **Feldman ED**, Wu PC, Beresneva T, Helsabeck C, Rodriguez M, Bartlett DL, Libutti SK, Pingpank JF, Alexander HR. Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion. *J Gastrointest Surg* 2004; **8**: 200-207 [PMID: 15036196 DOI: 10.1016/j.gassur.2003.11.005]

24 **Savier E**, Azoulay D, Huguet E, Lokiec F, Gil-Delgado M, Bismuth H. Percutaneous isolated hepatic perfusion for chemotherapy: a phase 1 study. *Arch Surg* 2003; **138**: 325-332 [PMID: 12611582 DOI: 10.1001/archsurg.138.3.325]

25 **Alexander HR**, Libutti SK, Bartlett DL, Pingpank JF, Kranda K, Helsabeck C, Beresnev T. Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy. *Cancer* 2002; **95**: 730-736 [PMID: 12209715 DOI: 10.1002/cncr.10686]

26 **Vahrmeijer AL**, van Dierendonck JH, Keizer HJ, Beijnen JH, Tollenaar RA, Pijl ME, Marinelli A, Kuppen PJ, van Bockel JH, Mulder GJ, van de Velde CJ. Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver. *Br J Cancer* 2000; **82**: 1539-1546 [PMID: 10789721 DOI: 10.1054/bjoc.2000.1175]

27 **Takahashi T**, Ku Y, Tominaga M, Iwasaki T, Fukumoto T, Takamatsu M, Tsuchida S, Sendou H, Suzuki Y, Kuroda Y. [Phase I study of super high-dose chemotherapy for liver cancer with percutaneous isolated hepatic perfusion (PIHP) and peripheral blood stem cell transplantation (PBSCT)]. *Gan To Kagaku Ryoho* 2000; **27**: 1801-1804 [PMID: 11086416]

28 **Alexander HR**, Libutti SK, Bartlett DL, Puhlmann M, Fraker DL, Bachenheimer LC. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. *Clin Cancer Res* 2000; **6**: 3062-3070 [PMID: 10955785]

29 **Lindnér P**, Fjälling M, Hafström L, Kierulff-Nielsen H, Mattsson J, Scherstén T, Rizell M, Naredi P. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan. *Eur J Surg Oncol* 1999; **25**: 179-185 [PMID: 10218462 DOI: 10.1053/ejso.1998.0623]

30 **Hwu WJ**, Salem RR, Pollak J, Rosenblatt M, D'Andrea E, Leffert JJ, Faraone S, Marsh JC, Pizzorno G. A clinical-pharmacological evaluation of percutaneous isolated hepatic infusion of doxorubicin in patients with unresectable liver tumors. *Oncol Res* 1999; **11**: 529-537 [PMID: 10905565]

31 **Oldhafer KJ**, Lang H, Frerker M, Moreno L, Chavan A, Flemming P, Nadalin S, Schmoll E, Pichlmayr R. First experience and technical aspects of isolated liver perfusion for extensive liver metastasis. *Surgery* 1998; **123**: 622-631 [PMID: 9626312 DOI: 10.1016/S0039-6060(98)70200-4]

32 **Oldhafer KJ**, Frerker MK, Lang H, Fauler J, Flemming P, Schmoll E, Nadalin S, Moreno L, Pichlmayr R. High-dose mitomycin C in isolated hyperthermic liver perfusion for unresectable liver metastases. *J Invest Surg* 1998; **11**: 393-400 [PMID: 9895113 DOI: 10.3109/08941939809032216]

33 **Nakajima Y**, Horikawa M, Kin T, Ohyama T, Kanehiro H, Hisanaga M, Nishio K, Nagao M, Sho M, Yamada T, Ohashi K, Ko S, Nakano H. Hyperthermo-chemo-hypoxic isolated liver perfusion for hepatic metastases: a possible adjuvant approach. *Recent Results Cancer Res* 1998; **147**: 28-41 [PMID: 9670266 DOI: 10.1007/978-3-642-80460-1\_4]

34 **Hafström L**, Naredi P. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia TNF alpha and melphalan: Swedish experience. *Recent Results Cancer Res* 1998; **147**: 120-126 [PMID: 9670274 DOI: 10.1007/978-3-642-80460-1\_12]

35 **Marinelli A**, de Brauw LM, Beerman H, Keizer HJ, van Bockel JH, Tjaden UR, van de Velde CJ. Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver. *Jpn J Clin Oncol* 1996; **26**: 341-350 [PMID: 8895675 DOI: 10.1093/oxfordjournals.jjco.a023243]

36 **Ravikumar TS**, Pizzorno G, Bodden W, Marsh J, Strair R, Pollack J, Hendler R, Hanna J, D'Andrea E. Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors. *J Clin Oncol* 1994; **12**: 2723-2736 [PMID: 7989950]

37 **Beheshti MV**, Denny DF, Glickman MG, Bodden W, Marsh JC, Strair R, Ravikumar TS. Percutaneous isolated liver perfusion for treatment of hepatic malignancy: preliminary report. *J Vasc Interv Radiol* 1992; **3**: 453-458 [PMID: 1515715 DOI: 10.1016/S1051-0443(92)71988-5]

38 **Lans TE**, Bartlett DL, Libutti SK, Gnant MF, Liewehr DJ, Venzon DJ, Turner EM, Alexander HR. Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion. *Clin Cancer Res* 2001; **7**: 784-790 [PMID: 11309322]

39 **Yamada T**, Hisanaga M, Nakajima Y, Kanehiro H, Aomatsu Y, Ko S, Kin T, Nishio K, Sho M, Nagao M, Harada A, Matsushima K, Nakano H. The serum interleukin 8 level reflects hepatic mitochondrial redox state in hyperthermochemohypoxic isolated liver perfusion with use of a venovenous bypass. *Surgery* 1999; **125**: 304-314 [PMID: 10076615 DOI: 10.1016/S0039-6060(99)70241-2]

40 **Wu PC**, McCart A, Hewitt SM, Turner E, Libutti SK, Bartlett DL, Alexander HR. Isolated organ perfusion does not result in systemic microembolization of tumor cells. *Ann Surg Oncol* 1999; **6**: 658-663 [PMID: 10560851 DOI: 10.1007/s10434-999-0658-3]

41 **Masucci IP**, Calis KA, Bartlett DL, Alexander HR, Horne MK. Thrombocytopenia after isolated limb or hepatic perfusions with melphalan: the risk of heparin-induced thrombocytopenia. *Ann Surg Oncol* 1999; **6**: 476-480 [PMID: 10458686 DOI: 10.1007/s10434-999-0476-7]

42 **De Vries MR**, Borel Rinkes IH, Swaak AJ, Hack CE, Van De Velde CJ, Wiggers T, Tollenaar RA, Kuppen PJ, Eggermont AM. Acute-phase response patterns in isolated hepatic perfusion with tumour necrosis factor alpha (TNF-alpha) and melphalan in patients with colorectal liver metastases. *Eur J Clin Invest* 1999; **29**: 553-560 [PMID: 10354218 DOI: 10.1046/j.1365-2362.1999.00480.x]

43 **Alexander HR**, Brown CK, Bartlett DL, Libutti SK, Figg WD, Raje S, Turner E. Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms. *Clin Cancer Res* 1998; **4**: 2357-2362 [PMID: 9796965]

44 **Kuppen PJ**, Jonges LE, van de Velde CJ, Vahrmeijer AL, Tollenaar RA, Borel Rinkes IH, Eggermont AM. Liver and tumour tissue concentrations of TNF-alpha in cancer patients treated with TNF-alpha and melphalan by isolated liver perfusion. *Br J Cancer* 1997; **75**: 1497-1500 [PMID: 9166943 DOI: 10.1038/bjc.1997.255]

45 **He X**, Kong Y, Wen D, Liu C, Xiao M, Zhao G, Zhen Y, Zhang H. A prospective, randomized trial of pancreatectomy combined with isolated hepatic perfusion via a dual route or conventional postoperative adjuvant therapy in patients with advanced pancreatic head carcinoma. *Int J Clin Exp Med* 2015; **8**: 6463-6471 [PMID: 26131274]

46 **Awazu M**, Fukumoto T, Takebe A, Ajiki T, Matsumoto I, Kido M, Tanaka M, Kuramitsu K, Ku Y. Lymphadenectomy combined with locoregional treatment for multiple advanced hepatocellular carcinoma with lymph node metastases. *Kobe J Med Sci* 2013; **59**: E17-E27 [PMID: 23756659]

47 **Alexander HR**, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. *J Clin Oncol* 1998; **16**: 1479-1489 [PMID: 9552055]

48 **Libutti SK**, Barlett DL, Fraker DL, Alexander HR. Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies. *J Am Coll Surg* 2000; **191**: 519-530 [PMID: 11085732 DOI: 10.1016/S1072-7515(00)00733-X]

49 **Bartlett DL**, Libutti SK, Figg WD, Fraker DL, Alexander HR. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. *Surgery* 2001; **129**: 176-187 [PMID: 11174711 DOI: 10.1067/msy.2001.110365]

50 **Rothbarth J**, Pijl ME, Vahrmeijer AL, Hartgrink HH, Tijl FG, Kuppen PJ, Tollenaar RA, van de Velde CJ. Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver. *Br J Surg* 2003; **90**: 1391-1397 [PMID: 14598420 DOI: 10.1002/bjs.4308]

51 **Alexander HR**, Libutti SK, Pingpank JF, Bartlett DL, Helsabeck C, Beresneva T. Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy. *Ann Surg Oncol* 2005; **12**: 138-144 [PMID: 15827794 DOI: 10.1245/ASO.2005.05.003]

52 **van Iersel LB**, Verlaan MR, Vahrmeijer AL, van Persijn van Meerten EL, Tijl FG, Sparidans RW, Gelderblom H, Kuppen PJ, Tollenaar RA, van de Velde CJ. Hepatic artery infusion of high-dose melphalan at reduced flow during isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: a clinical and pharmacologic evaluation. *Eur J Surg Oncol* 2007; **33**: 874-881 [PMID: 17400422 DOI: 10.1016/j.ejso.2007.02.022]

53 **van Iersel LB**, Koopman M, van de Velde CJ, Mol L, van Persijn van Meerten EL, Hartgrink HH, Kuppen PJ, Vahrmeijer AL, Nortier JW, Tollenaar RA, Punt C, Gelderblom H. Management of isolated nonresectable liver metastases in colorectal cancer patients: a case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy. *Ann Oncol* 2010; **21**: 1662-1667 [PMID: 20110289 DOI: 10.1093/annonc/mdp589]

54 **Schepers A**, Mieog S, van de Burg BB, van Schaik J, Liefers GJ, Marang-van de Mheen PJ. Impact of complications after surgery for colorectal liver metastasis on patient survival. *J Surg Res* 2010; **164**: e91-e97 [PMID: 20851414 DOI: 10.1016/j.jss.2010.07.022]

55 **Olofsson R**, Cahlin C, All-Ericsson C, Hashimi F, Mattsson J, Rizell M, Lindnér P. Isolated hepatic perfusion for ocular melanoma metastasis: registry data suggests a survival benefit. *Ann Surg Oncol* 2014; **21**: 466-472 [PMID: 24141377 DOI: 10.1245/s10434-013-3304-z]

56 **Magge D**, Choudry HA, Zeh HJ, Cunningham DE, Steel J, Holtzman MP, Jones HL, Pingpank JF, Bartlett DL, Zureikat AH. Outcome analysis of a decade-long experience of isolated hepatic perfusion for unresectable liver metastases at a single institution. *Ann Surg* 2014; **259**: 953-959 [PMID: 24169176 DOI: 10.1097/SLA.0000000000000261]

57 **Fukumoto T**, Tominaga M, Kido M, Takebe A, Tanaka M, Kuramitsu K, Matsumoto I, Ajiki T, Ku Y. Long-term outcomes and prognostic factors with reductive hepatectomy and sequential percutaneous isolated hepatic perfusion for multiple bilobar hepatocellular carcinoma. *Ann Surg Oncol* 2014; **21**: 971-978 [PMID: 24201744 DOI: 10.1245/s10434-013-3305-y]

58 **Alexander HR**, Bartlett DL, Libutti SK, Pingpank JF, Fraker DL, Royal R, Steinberg SM, Helsabeck CB, Beresneva TH. Analysis of factors associated with outcome in patients undergoing isolated hepatic perfusion for unresectable liver metastases from colorectal center. *Ann Surg Oncol* 2009; **16**: 1852-1859 [PMID: 19434456 DOI: 10.1245/s10434-009-0482-9]

59 **van Iersel LB**, Gelderblom H, Vahrmeijer AL, van Persijn van Meerten EL, Tijl FG, Putter H, Hartgrink HH, Kuppen PJ, Nortier JW, Tollenaar RA, van de Velde CJ. Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients. *Ann Oncol* 2008; **19**: 1127-1134 [PMID: 18304962 DOI: 10.1093/annonc/mdn032]

60 **Rizell M**, Mattson J, Cahlin C, Hafström L, Lindner P, Olausson M. Isolated hepatic perfusion for liver metastases of malignant melanoma. *Melanoma Res* 2008; **18**: 120-126 [PMID: 18337648 DOI: 10.1097/CMR.0b013e3282f8e3c9]

61 **Pingpank JF**, Libutti SK, Chang R, Wood BJ, Neeman Z, Kam AW, Figg WD, Zhai S, Beresneva T, Seidel GD, Alexander HR. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. *J Clin Oncol* 2005; **23**: 3465-3474 [PMID: 15908655 DOI: 10.1200/JCO.2005.00.927]

62 **Alexander HR**, Libutti SK, Pingpank JF, Steinberg SM, Bartlett DL, Helsabeck C, Beresneva T. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. *Clin Cancer Res* 2003; **9**: 6343-6349 [PMID: 14695133]

63 **Kim WR**, Gores GJ, Benson JT, Therneau TM, Melton LJ. Mortality and hospital utilization for hepatocellular carcinoma in the United States. *Gastroenterology* 2005; **129**: 486-493 [PMID: 16083705 DOI: 10.1016/j.gastro.2005.05.001]

64 **Surbone A**, DeVita VT. Dose intensity. The neglected variable in clinical trials. *Ann N Y Acad Sci* 1993; **698**: 279-288 [PMID: 8279768 DOI: 10.1111/j.1749-6632.1993.tb17219.x]

65 **de Brauw LM**, Marinelli A, van de Velde CJ, Hermans J, Tjaden UR, Erkelens C, de Bruijn EA. Pharmacological evaluation of experimental isolated liver perfusion and hepatic artery infusion with 5-fluorouracil. *Cancer Res* 1991; **51**: 1694-1700 [PMID: 1998960]

66 **AUSMAN RK**. Development of a technic for isolated perfusion of the liver. *N Y State J Med* 1961; **61**: 3993-3997 [PMID: 13863315]

67 **Curley SA**, Byrd DR, Newman RA, Carrasco CH, Cromeens D, Ellis HJ, Chase J, Dougherty T, Wright K, Bodden W. Hepatic arterial infusion chemotherapy with complete hepatic venous isolation and extracorporeal chemofiltration: a feasibility study of a novel system. *Anticancer Drugs* 1991; **2**: 175-183 [PMID: 1958862 DOI: 10.1097/00001813-199104000-00008]


68 **Urade T**, Tanaka M, Fukumoto T, Kido M, Tsuchida S, Takahashi M, Takebe A, Kuramitsu K, Awazu M, Chuma M, Fukushima K, So S, Tai K, Fujimoto M, Toyama H, Shinzeki M, Matsumoto I, Ajiki T, Ku Y. [A case of bilobar multiple hepatocellular carcinoma in which complete remission was achieved by preoperative percutaneous isolated hepatic perfusion and subsequent hepatectomy]. *Gan To Kagaku Ryoho* 2012; **39**: 1825-1827 [PMID: 23267899]

69 **Toyama H**, Matsumoto I, Shinzeki M, Shirakawa S, Tanaka M, Yamashita H, Ajiki T, Ueno K, Sawa H, Otsubo I, Murakami S, Kido M, Fukumoto T, Ku Y. [A case of postoperative liver metastasis from pancreatic carcinoma treated with percutaneous isolated hepatic perfusion(PIHP)]. *Gan To Kagaku Ryoho* 2012; **39**: 1886-1888 [PMID: 23267919]


70 **Maeda I**, Ku Y, Iwasaki T, Sugimoto T, Kusunoki N, Kuroda Y, Saitoh Y. [A case of advanced cholangiocellular carcinoma treated successfully by percutaneous isolated liver perfusion with cisplatin]. *Gan To Kagaku Ryoho* 1996; **23**: 1607-1609 [PMID: 8854818]

71 **Pingpank JF**. Melphalan for colorectal metastases to the liver. *Clin Adv Hematol Oncol* 2010; **8**: 175-177 [PMID: 20400932]


**P-Reviewer:** Akamatsu N **S-Editor:** Qiu S **L-Editor: E-Editor:**




**Figure 1 Literature search PRIMSA flow diagram.**




**Figure 2 Forest plot of the studies for response rate.** Pooled estimate (%) = 60.8%, 95%CI: 53.1%-68.0%, *I2* = 37.1%.



**Figure 3 Forest plot of the studies for mortality.** Pooled estimate (%) = 5.4%, 95%CI: 2.5%-11.2%, *I2* = 37.5%.



**Figure 4 Forest plot of the relative risk of overall survival for different gender.**



**Figure 5 Forest plot of the relative risk of overall survival for different preoperative carcino-embryonic antigen levels.**

**Table 1 Summary of data points presented in relevant clinical trials**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Yr** | **Country** | **Research institution** | **Study period** | **MINORS score** | **IHP patients**  **(*n*)** | **Tumor**  **details** | **Eligibility and exclusion criteria** | **IHP details and response rate** | **Morbidity and mortality** | **Complications and toxicities** | **Long-term survival** | **Prognostic factors** |
| Olofsson *et al*[55] | 2014 | Sweden | The Swedish National Board of Health and Welfare | April 2005 to March 2011 | 18 | 34 | Y | Y | Y | Y | Y | Y | Y |
| Magge *et al*[56] | 2014 | United States | University of Pittsburgh Cancer institute | November 2003 to February 2012 | 12 | 91 | Y | NR | Y | Y | Y | Y | Y |
| Fukumoto *et al*[57] | 2014 | Japan | The Kobe University Hospital | January 1989 to December 2010 | 12 | 68 | Y | Y | Y | NR | Y | Y | Y |
| Alexander *et al*[58] | 2009 | United States | NCI | June 1994 to July 2005 | 12 | 120 | Y | Y | Y | Y | Y | Y | Y |
| Iersel *et al*[59] | 2008 | Netherlands | Leiden University Medical Center | August 1994 to December 2004 | 12 | 105 | Y | Y | Y | Y | Y | Y | Y |
| Rizell *et al*[60] | 2008 | Sweden | Sahlgrenska University Hospital | 1985 to 2007 | 11 | 27 | Y | Y | Y | Y | Y | Y | NR |
| Pingpank *et al*[61] | 2005 | United States | NCI | July 2001 to January 2004 | 12 | 28 | Y | Y | Y | Y | Y | NR | NR |
| Alexander *et al*[62] | 2003 | United States | NCI | December 1997 to August 2002 | 12 | 29 | Y | Y | Y | Y | Y | Y | Y |

Y: Recorded data available; NR: Not reported; NCI: The National Cancer Institute.

**Table 2 Patient demographics and disease characteristics**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Patients**  **(*n*)** | **Age**  **(median)** | **Male: Female** | **Primary tumor** | **Primary tumor treatment**  ***n* (%)** | | | **Liver involvement *n* (%) or**  **mean percentage (range)** | | | **Number of liver metastases** | **Largest liver metastases diameter (cm), median (range)** | **Extra-hepatic metastases**  ***n* (%)** |
|  |  |  |  |  | excision | Chemotherapy | No treatment | < 5% | 25%-0% | > 0% |  |  |  |
| Olofsson *et al*[55] | 34 | 61  (17-77) | 15:19 | Ocular melanoma | 15 (44%) | 19 (56%) | None | 31 (91%) | 3 (9%) | None | 1-100 31 (91%)  > 100 3(9%)) | 2.35 (1.0-6.4) | None |
| Magge *et al*[56] | 91 | 54.3  (24-77) | 50:41 | CRC 54 (59.3%)  Ocular melanoma 29 (32%)  Others 8 (8.7%) | None | CRC 47 (87%) | 44 (48%) | 30% (5%-80%) | | | 9 (2-105) | NR | NR |
| Fukumoto *et al*[57] | 68 | 60  (52-67) | 61:7 | HCC | 68 (100%) | NR | None | NR | NR | NR | ≥ 4 | 8.3 (5.0-12.6) | None |
| Alexander *et al*[58] | 120 | 52  (22-74) | 41:79 | CRC | NR | NR | NR | 20% (5%-75%) | | | NR | 8 (1-50) | NR |
| Iersel *et al*[59] | 105 | ≤ 70 | 78:27 | CRC | 4 (3.8%) | 51 (48.6%) | 50 (47.6%) | NR | NR | NR | < 10 71 (68%)  ≥ 10 34 (32%) | NR | 34 (32.4%) |
| Rizell *et al*[60] | 27 | 53 (36-77) | NR | Melanoma | NR | NR | NR | 6 (22%) | 11 (41%) | 10 (37%) | NR | NR | NR |
| Pingpank *et al*[61] | 28 | 49  (17-74) | 14:14 | Melanoma 13  CRC 2  Others 13 | NR | NR | NR | NR | NR | NR | NR | NR | 8 (29%) |
| Alexander *et al*[62] | 29 | 49  (26-73) | 15:14 | Ocular melanoma | NR | NR | NR | 20 (69%) | 8 (28%) | 1 (3%) | 25 (4 ≥ 50) | 5.6 (2-14) | NR |

CRC: Colorectal cancer; HCC: Hepatocellular carcinoma; NR: Not reported.

**Table 3 Isolated hepatic perfusion details and response rate**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Patients evaluable for response (*n*)** | **IHP/PIHP** | **IHP chemotherapy protocol** | | | | | **Patient response** | | | | **Overall response**  **(CR + PR, %)** |
|  |  |  | Drug | Dose | Perfusion temperature | Perfusion time | Courses per patient (*n*) | Complete  Response (%) | Partial response (%) | Stable  Disease (%) | Progressive  Disease (%) |  |
| Olofsson *et al*[55] | 34 | IHP | Melphalan | 1 mg/kg | 40 ℃ | 60 min | 1 | 4 (12%) | 19 (56%) | 6 (18%) | 5 (15%) | 68% |
| Magge *et al*[56] | 68 | IHP | Melphalan  Oxaliplatin  Oxaliplatin+5FU | 1.5 mg/kg  40 mg/m2  5FU 200 mg/m2 | 40 ℃ | 60 min | 1 | 44 (64.7%) | | 24 (35.3%) | | 64.7% |
| Fukumoto *et al*[57] | 67 | PIHP | Mitomycin C and/or  Doxorubicin | 20-40 mg/m2  60-120 mg/m2 | NR | 30-40min | 1.51  (range 1-3) | 21 (31.3%) | 27 (40.3%) | 11 (16.4%) | 8 (11.9%) | 71.6% |
| Alexander *et al*[58] | 114 | IHP | Melphalan  TNF alone  Or both | 1.5 mg/kg  1 mg | 39.5-40 ℃ | 60min | 1 | 2 (1.8%) | 67 (58.8%) | NR | NR | 60.5% |
| Iersel *et al*[59] | 97 | IHP | Melphalan | 200 mg | 39.5 ℃ | 60min | 1 | 3 (3.1%) | 49 (50.5%) | 23 (23.7%) | 22 (22.7%) | 53.6% |
| Rizell *et al*[60] | 27 | IHP | Melphalan  With or without  TNF | 0.5, 1 and 2 mg/kg  30 μg | ≥ 40 ℃ | 40-60min | 1 | 2 (7.4%) | 17 (63.0%) | 2 (7.4%) | 6 (22.2%) | 69.4% |
| Pingpank *et al*[61] | 27 | PIHP | Melphalan | 2-3.5 mg/kg | NR | 60 min | 2.64 | 2 (7.4%) | 6 (22.2%) | NR | NR | 29.6% |
| Alexander *et al*[62] | 29 | IHP | Melphalan | 1.5 mg/kg | NR | 60 min | 1 | 3 (10%) | 15 (52%) | NR | NR | 62% |

NR: Not reported.

**Table 4 Isolated hepatic perfusion morbidity and mortality**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Toxicity Grade 3/4 (%)** | | | | | | **Complications Grade 3/4 (%)** | | | | |
| **Ref.** | **Mortality** | **Bilirubin** | **Transaminases** | **Alkaline phosphatase** | **Neutropenia** | **Platelets** | **Anemia** | **Hepatic artery obstruction** | **Hepatic failure** | **Bleeding** | **Hypotension** | **Wound infection** |
| Olofsson *et al*[55] | None | NR | NR | NR | NR | NR | NR | 2.90% | NR | NR | NR | NR |
| Magge *et al*[56] | 3.30% | 20.50% | 50.00% | 3.40% | 2.30% | 18.20% | 50.00% | NR | 5.70% | NR | 0% | 3.40% |
| Fukumoto *et al*[57] | NR | NR | 77.90% | NR | 44.10% | NR | NR | NR | NR | 1.50% | NR | 8.80% |
| Alexander *et al*[58] | 4% | 46.70% | 55.80% | 4.20% | 0.80% | 10.00% | NR | NR | 3.30% | 0.80% | 5.80% | 2.50% |
| Iersel *et al*[59] | 6% | 18.00% | 20.00% | 15.20% | 2.90% | NR | NR | 1.90% | NR | 8.60% | NR | NR |
| Rizell *et al*[60] | 22% | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Pingpank *et al*[61] | None | 18.9% (hepatic toxicity) | | | 66.20% | 35.10% | 17.60% | NR | NR | NR | NR | NR |
| Alexander *et al*[62] | None | 65.5% (hepatic toxicity) | | | NR | NR | NR | NR | NR | NR | NR | NR |
| Pooled P  (95%) CI | 5.4% (2.5%-11.2%) |  |  |  | 10.3 （2%-39%） | 19.2 (8.7%-37.2%) | 31.9% (9.3%-68.1%) | 2.2% (0.7%-6.6%) | 4.5% (2.3%-8.4%) | 4.5%  (1.8-11.1%) | 2.7% (0.3%-20.3%) | 5.7% (3.1%-10.2%) |

NR: Not reported.

**Table 5** **Long-term survival outcomes after isolated hepatic perfusion**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Median follow up**  **(mo)** | **Median time to local progression (mo)** | **Median time to systemic progression (mo)** | **Median hepatic progression-free survival (mo)** | **Overall survival** | | | | | |
|  |  |  |  |  | Median OS (mo from IHP) | 1-year survival  (%) | 2-year survival  (%) | 3-year survival  (%) | 4-year survival  (%) | 5-year survival  (%) |
| Olofsson *et al*[55] | NR | 7 (0-31) | 13(2-34) | NR | 24 | NR | NR | NR | NR | NR |
| Magge *et al*[56] | NR | NR | NR | For CRC group: 12 (10.53-13.47)  For CR: 12  For PR: 12 (10.1-13.9)  For SD: 12.5 (10.53-13.47) | 23 (15-28) | NR | NR | NR | NR | NR |
| Fukumoto *et al*[57] | 20 (3-191) | NR | NR | NR | 25 | 80.6% | NR | 35.7% | NR | 27.6% |
| Alexander *et al*[58] | 78.1 (52.1-104.2) | 7.3 (6.5-8.0) | | NR | 25 (19.4-30.6) | NR | 53% | 28% | 14% | NR |
| Iersel *et al*[59] | NR | NR | NR | 7 | 17.4 | NR | 34% | NR | NR | NR |
| Rizell *et al*[60] | IHP I cohort: NR  IHP II cohort: NR  IHP III cohort: 7 (range 4-18) | NR | NR | NR | 12.6 (2.5-57) | NR | NR | NR | NR | NR |
| Alexander *et al*[62] | 11 (3-40) | 8 | | 12 | 12.1 (3-39+) | NR | NR | NR | NR | NR |
| Median value (range) |  |  | |  | 20 (12.1-25) |  |  |  |  |  |

OS: Overall survival; NR: Not reported; CRC: Colorectal cancer; CR: Complete response; PR: Partial response; SD: Stable disease.

**Table 6 Summary of prognostic factors presented in relevant clinical trials**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.** | **Yr** | **Prognostic factors for response** | **Prognostic factors for TTLP** | **Prognostic factors for PFS** | **Prognostic factors for OS** |
| Olofsson *et al*[55] | 2014 | NR | Y | NR | Y |
| Magge *et al*[56] | 2014 | Y | NR | NR | Y |
| Fukumoto *et al*[57] | 2014 | NR | NR | NR | Y |
| Alexander *et al*[58] | 2009 | Y | NR | Y | Y |
| Iersel *et al*[59] | 2008 | Y | NR | Y | Y |
| Rizell *et al*[60] | 2008 | NR | NR | NR | NR |
| Pingpank *et al*[61] | 2005 | NR | NR | NR | NR |
| Alexander *et al*[62] | 2003 | Y | NR | NR | Y |

TTLP: Time to local progression; PFS: Progression free survival; OS: Overall survival; NR: Not reported.